November 1, 2019

RadOnc Biostatistics Talk

11:00 AM to 12:00 PM

RadOnc Conference Room
UH B2C430

Contact Samantha Harbacuk

Please join my meeting from your computer, tablet or smartphone.
https://global.gotomeeting.com/join/254184086

Join the conference call:
734-997-7110 @ prompt press 3103#

If you have any issues please contact Steven Jordan
New to GoToMeeting? Get the app now and be ready when your first meeting starts: https://global.gotomeeting.com/install/254184086

Meredith M Regan, ScD, Assoc. Professor: Harvard Medical School & Dana-Farber Cancer Institute

Biostatistics

Speaking on- Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP): MFS and DFS, but not EFS, are Valid Surrogate Endpoints for Overall Survival.

Meredith Regan

Associate Professor

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Associate Professor, Biostatistics and Computational Biology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION